#USA #San Diego #diagnostics #Invetech #General Fluidics

Strategic Partnership: General Fluidics and Invetech

In a groundbreaking move in healthcare technology, General Fluidics (GF) has announced a strategic partnership with Invetech to revolutionize diagnostic accessibility at points of care. This collaboration aims to bring high-quality diagnostics directly to patients, ensuring faster decision-making, improved health outcomes, and broader healthcare access.

Redefining Diagnostic Testing

Founded at Massachusetts General Hospital, General Fluidics is on a mission to transform routine blood testing by relocating processes from traditional central labs to clinics and immediate care settings. Their innovative platform, Axess, is designed to make reference-laboratory-quality diagnostics available within minutes, even in rural and urgent care environments. This transition signifies a pivotal step towards making healthcare services more accessible and efficient, ultimately benefiting patient care.

Selection of Invetech: A Strategic Decision

After an extensive global search for a capable partner, GF selected Invetech for its deep experience and proven track record in developing complex diagnostic technologies. Rob Granier, CEO of General Fluidics, emphasized the critical nature of this collaboration, noting the need for a partner that can not only address complex challenges but also support their rapid scaling. Invetech's ability to provide a combination of technical expertise and partnership values was a decisive factor in this selection.

Invetech's Unique Capabilities

Invetech brings an impressive array of capabilities to the table, with decades of experience in translating intricate diagnostic technologies into manufacturable and regulated products. Their reputation for commercial insight, risk management, and execution at every development stage makes them a robust ally in this venture. According to Andreas Knaack, CEO of Invetech, the timely convergence of market readiness and technological maturity presents a fantastic opportunity to push for decentralized testing solutions.

Focus on Collaboration and Execution

The collaboration between General Fluidics and Invetech is underscored by a shared vision and leadership commitment to efficiently execute their plans. This alignment not only expedites innovation but also enhances their capacity to make a significant impact on the healthcare landscape. By harnessing both companies' strengths, they aim to deliver high-quality diagnostics to a broader patient base at an unprecedented pace.

About Invetech

Invetech stands out as a trusted partner in tackling intricate manufacturing and product development challenges, particularly in the global advanced therapies and diagnostics market. With over three decades of partnership with leaders in diagnostics, life sciences, and cell therapy sectors, Invetech has co-created transformative solutions that turn ideas into market-ready technologies. Their expertise ranges from early process development to optimizing complex workflows, which significantly advances the healthcare industry.

About General Fluidics

Founded in 2018, General Fluidics is a Boston-based diagnostic company focused on making testing more accessible for all patients. Their compact, integrative benchtop lab, the Axess platform, offers hundreds of high-quality diagnostic tests at the point of care, providing results in minutes. By delivering advanced diagnostic capabilities directly within reachable locations, General Fluidics is well-positioned to change the healthcare narrative considerably.

Through this partnership, General Fluidics and Invetech are pioneering innovative solutions designed to address critical healthcare needs. The seamless integration of cutting-edge diagnostics into everyday healthcare settings marks a revolutionary shift towards improved patient care, one that promises to enhance outcomes and accessibility for all.